Krause David S, Dowd Daniel
Genomind Inc., King of Prussia, 2200 Renaissance Blvd 100, PA 19406, USA.
Pharmacogenomics. 2022 Apr;23(5):327-333. doi: 10.2217/pgs-2021-0121. Epub 2022 Mar 17.
The emerging discipline of pharmacogenetics (PGx) has the goal of aiding the selection of effective therapies and personalized dosing, decreasing the likelihood of adverse drug reactions and optimizing resource utilization. Simultaneously, the rapid evolution of economically feasible genetic testing technologies has resulted in a raft of commercial entities that provide genetic data to providers for use with their complex patients. The adoption of pharmacogenomics in psychiatry is growing, but it is limited by several factors, including the limitless permutations of drugs, comorbid conditions and concomitant medications and provider understanding of phenomena such as phenoconversion. We established an expert PGx consultation service for psychiatric providers who utilize our commercial PGx assay. To date, this service has provided ∼16,000 consults with extremely high levels of satisfaction; in an anonymous survey, 96% of respondents reported a rating of "very helpful" or "extremely helpful".
新兴的药物遗传学（PGx）学科旨在帮助选择有效的治疗方法和个性化给药方案，降低药物不良反应的可能性，并优化资源利用。同时，经济可行的基因检测技术的迅速发展催生了大量商业实体，这些实体为医疗服务提供者提供基因数据，供其用于复杂患者。药物基因组学在精神病学中的应用正在增加，但受到多种因素的限制，包括药物的无限组合、共病情况和联合用药，以及医疗服务提供者对表型转换等现象的理解。我们为使用我们商业PGx检测的精神病学医疗服务提供者建立了专家PGx咨询服务。迄今为止，这项服务已提供了约16000次咨询，满意度极高；在一项匿名调查中，96%的受访者表示评价为“非常有帮助”或“极其有帮助”。
